Dear members, please see below MedTech Europe update on EU REACH and CLP. If you have these substances in your products that you place in the EU or Northern Ireland markets, please let us know.
We would like to inform you on the latest news from ECHA and ask you for your input and feedback on recent REACH and CLP proposals. We kindly ask you to indicate if any of the following are of relevance for you by 13 September:
- Proposals to identify a substance of very high concern:
- 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid (EC 701-118-1, CAS 2156592-54-8).
- O,O,O-triphenyl phosphorothioate (EC 209-909-9, CAS 597-82-0).
- Octamethyltrisiloxane (EC 203-497-4, CAS 107-51-7). Please note that the proposal lists medical and healthcare applications among the identified uses, which might be relevant for members.
- Perfluamine (EC 206-420-2, CAS 338-83-0).
- Reaction mass of: triphenylthiophosphate and tertiary butylated phenyl derivatives (EC 421-820-9, CAS 192268-65- 8).
- Tris(4-nonylphenyl, branched and linear) phosphite (EC 701-028-2).
- Proposal to harmonise classification and labelling:
-
- 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthyl)ethan-1-one (EC 216-133-4; 244-240-6, CAS 1506-02-1; 21145-77-7).
